CHICAGO -- In this Healio Video Perspective from the AAO meeting, Matthew Giegengack, MD, of Wake Forest University discusses the outcomes of corneal endothelial cell therapy for endothelial dysfunction.

The study's benchmarks for measuring efficacy outcomes were best corrected visual acuity and brightness acuity testing.

"The results are really promising," Giegengack said.

Both measurements improved over the course of 1 year, demonstrating the potential for corneal endothelial cell therapy to improve vision and treat glare, he said.